Hemorrhagic disease

Researchers are testing denecimig, an experimental antibody given as an injection under the skin, in adults newly diagnosed with acquired haemophilia A. This rare condition causes the immune system to attack a clotting protein, leading to sudden and sometimes severe bleeding. The…

This trial tests whether adding a selective Mediterranean diet to standard treatment can improve platelet counts and reduce bleeding in adults with immune thrombocytopenia (ITP), a condition where the immune system attacks platelets. Sixty adults aged 18 to 60 with low platelet c…

This early-stage trial tests a gene therapy for people with hemophilia A, a bleeding disorder. The treatment uses a modified virus to deliver a working gene into the patient's own stem cells, which are then infused back. The goal is to help the body produce clotting factor VIII, …

This study compares two blood thinners—apixaban (Eliquis) and warfarin (Coumadin)—in 460 people with advanced heart failure who have a HeartMate 3 heart pump. The goal is to see which drug better prevents strokes, pump clots, and serious bleeding. Participants must have had their…

This trial tests whether giving patients extra protein and saline mist after tonsillectomy helps them heal faster and avoid complications. Tonsil removal is common in children and adults, but it often causes pain, trouble swallowing, and a risk of bleeding. The researchers will c…

This trial tests whether an experimental drug called bometase alfa can safely stop bleeding episodes in people with acquired hemophilia A, a rare condition where the immune system attacks a key blood-clotting protein. About 20 adults with active bleeding will receive the drug by …

This phase 1 trial tests a one-time infusion of AZD0120, a CAR-T cell therapy that targets CD19 and BCMA, in people with relapsed or refractory immune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA). Participants receive a short course of bendamustine before th…

This trial tests whether elranatamab, a drug used in cancer, can safely and effectively eliminate factor VIII inhibitors in adults with moderate-to-severe hemophilia A. Participants receive weekly injections for three weeks, with a follow-up period to monitor changes in inhibitor…

This Phase 1 trial tests a gene therapy that uses a lentivirus to deliver a working clotting factor IX gene into patients' own stem cells. Ten males with severe hemophilia B will receive the modified cells. The goal is to see if it's safe and can raise clotting factor levels, pot…

This trial tests whether a newer acid-reducing drug, vonoprazan, is better than a double dose of the standard drug esomeprazole at preventing rebleeding in people who have had a bleeding stomach or intestinal ulcer treated with endoscopy. About 108 adults at high risk of rebleedi…

This study tests whether sivelestat, a drug used in Japan for lung injury, can help restore the body's ability to break down harmful blood clots in people with septic shock. About 120 adults with septic shock and early blood clotting problems will receive either sivelestat or a p…

This phase 4 trial tests whether Altuviiio (efanesoctacog alpha) can help children with severe hemophilia A and high-titer inhibitors achieve immune tolerance. Participants also receive Hemlibra (emicizumab) to prevent bleeding. The study involves 15 children under 18 and will tr…

This trial tests whether inebilizumab, an antibody that wipes out certain immune cells called B cells, can improve physical function in adults with ME/CFS that started after an infection. Participants receive three infusions over six months, and the study measures changes in mobi…

This phase II trial tests an injected drug called SR604 in people with congenital Factor VII deficiency, a rare bleeding disorder. The goal is to see if SR604 can reduce the number of bleeding episodes and improve safety. The study includes 12 participants aged 12 to 65 who have …

This phase 2 trial tests a personalized CAR T cell therapy called zolacabtagene autoleucel in 52 adults with chronic immune thrombocytopenia (ITP) or autoimmune hemolytic anemia (AIHA). The treatment uses the patient's own immune cells, modified to target and destroy faulty B cel…

This study looks at 112 people with immune thrombocytopenia (ITP) whose platelet counts didn't improve after standard treatment with rhTPO. After a two-week break, they will either get a higher dose of rhTPO or switch to a different drug called eltrombopag. The goal is to see whi…

This observational study will follow 40 children aged 7 to 12 with hemophilia A who are already prescribed damoctocog alfa pegol (Jivi) to prevent bleeding. Researchers will collect data from routine care, including bleeding episodes and treatment patterns, over two years. The go…

This trial investigates whether combining atorvastatin (a cholesterol-lowering drug), N-acetyl-L-cysteine (an antioxidant), and romiplostim (a platelet-boosting drug) can help adults with immune thrombocytopenia (ITP) who no longer respond to steroids. The goal is to see if this …

This phase 2 trial tests whether adding baricitinib to standard TPO-RA therapy helps adults with immune thrombocytopenia (ITP) who did not respond to TPO-RA alone. One hundred participants will be randomly assigned to receive either baricitinib plus TPO-RA or TPO-RA alone for 14 …

This phase 2 trial tests whether adding ianalumab to eltrombopag helps children aged 5 to 17 with primary immune thrombocytopenia (ITP) who didn't improve after steroids. The goal is to see if the combination can raise platelet counts and prevent bleeding. About 36 children will …

This study tests whether a new shelf-stable blood product (IFC) works faster than the standard cryoprecipitate to stop severe bleeding in trauma patients. About 320 adults with traumatic injuries and low fibrinogen levels will be enrolled. The goal is to see if IFC can be given m…

This study looks at the safety and effectiveness of Octocog alfa, a lab-made clotting factor, when used to treat sudden bleeding episodes in adults with severe hemophilia A. About 33 people in India who have used factor VIII before will take part. Researchers will track side effe…

This study tests whether patients with a heart pump (LVAD) can safely stop taking aspirin while continuing warfarin. The goal is to reduce bleeding problems without increasing dangerous clots. About 370 participants will be randomly assigned to receive either aspirin or a placebo…

This early-stage study tests a new drug called JCXH-213 in adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The trial includes only 4 people whose ITP did not improve with standard treatments. The main goal is to…

This study tests all-trans retinoic acid (ATRA), a form of vitamin A, in adults with immune thrombocytopenia (ITP) whose platelet counts stay low despite steroid treatment. About 192 participants will receive either ATRA or a placebo for 24 weeks. The goal is to see if ATRA can s…

This study will test a combined procedure in 150 people with atrial fibrillation (AFib) who are at risk for stroke. Doctors will use pulse field ablation to correct the heart's rhythm and then close off a small pouch in the heart (the left atrial appendage) to prevent blood clots…

This early-phase trial tests a new drug called TGD001 in about 70 adults with acute episodes of immune-mediated thrombotic thrombocytopenic purpura (iTTP) or related blood clotting conditions. The main goal is to check the drug's safety and how the body processes it, while also l…

This phase 3 trial tests QL0911, a weekly injection, in 60 children aged 1 to 17 with chronic immune thrombocytopenia (ITP) who have low platelet counts. The goal is to see if the drug can safely raise platelet levels to reduce bleeding risk. Participants receive either QL0911 or…

This early-phase trial will test a new type of CAR T-cell therapy, called QT-019C, in 27 adults with refractory immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The therapy uses donor-derived immune cells engineered to targe…

This phase 2 study tests whether combining orelabrutinib (a targeted drug) with romiplostim (a platelet booster) can improve platelet counts in adults with chronic immune thrombocytopenia (ITP) who haven't responded well to standard treatments. About 28 participants will receive …

This study tests a new procedure using an endoscopic ultrasound to guide the injection of tiny particles into the spleen, reducing blood flow and lowering the risk of dangerous bleeding in people with liver cirrhosis. The goal is to see if this method is safer and more effective …

This early-stage trial is testing three different daily doses of zanubrutinib (80, 160, or 240 mg) combined with high-dose dexamethasone in 60 adults newly diagnosed with immune thrombocytopenia (ITP). The goal is to find the safest and most effective dose that helps maintain pla…

This study tests whether adding all-trans retinoic acid (ATRA) to the drug avatrombopag can help adults with immune thrombocytopenia (ITP) maintain normal platelet levels without needing ongoing treatment. About 248 participants who have not responded well to first-line therapy o…

This study tests a drug called romiplostim, given as a weekly shot, in 100 children aged 1 to 18 with chronic immune thrombocytopenia (ITP) who haven't been helped by standard treatments. The goal is to see if it can safely raise platelet counts and reduce bleeding. Children will…

This early-stage trial tests golidocitinib, an oral drug, in adults with immune thrombocytopenia (ITP) whose platelet counts remain low despite prior treatments. The study has two parts: first, finding a safe dose, then comparing the drug against a placebo in a blinded fashion. T…

This study tests whether giving tranexamic acid (TXA) through a vein during weight-loss surgery can reduce blood loss in patients with a very high body mass index (BMI over 45). About 128 high-risk adults will receive TXA or a placebo to see if it lowers the need for blood transf…

This study will follow 20 children with hemophilia A who are starting emicizumab treatment. Researchers will measure pain, joint health, balance, and mobility over time to see if the drug helps protect the musculoskeletal system. The goal is to understand whether emicizumab can r…

This study tests a three-step treatment for adults with severe immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. Participants first get steroids and a platelet-boosting protein in the hospital, then switch to an oral drug (el…

This study tests whether giving dry plasma to people with massive bleeding before they reach the hospital can improve survival. Researchers will compare dry plasma to standard fluids in 650 adults with signs of bleeding shock. The main goal is to see if more people survive the fi…

This phase 3 trial will compare two second-line treatments for immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risk. About 220 adults who didn't respond to steroids will be randomly assigned to take avatrombopag (a daily pil…

Researchers are testing an AI software tool called DSA-VDet v1.0 that highlights suspected bleeding on angiography images in real time. The trial enrolls adults with suspected acute bleeding in various body regions who need a digital subtraction angiography (DSA) procedure. Docto…

This study tests whether a mechanical 3D ultrasound device can detect joint damage in people with hemophilia as accurately as a full ultrasound or MRI. Eleven participants will have their ankles scanned with the new device. If it works well, it could offer a faster, less expensiv…

This study tests whether a low dose of aripiprazole, a drug used for psychiatric conditions, can reduce fatigue and improve thinking in adults with Long COVID or other post-infection syndromes. About 138 participants will receive either the drug or a placebo for 8 weeks, then swi…

This study tests whether taking ginger powder for the first three days of each period can reduce heavy menstrual bleeding in women with coagulation disorders (bleeding problems). 74 women will be randomly assigned to receive either ginger or a placebo for six cycles. The goal is …

This study tests whether a structured educational program can help adults with hemophilia who have chronic joint pain. The program teaches about pain, emotions, and coping strategies. 70 participants will be randomly assigned to either the education program or usual care, and the…

This study tests whether a virtual reality exercise program using Kinect Xbox can improve joint health, balance, and quality of life in 20 boys aged 6-18 with hemophilia A. Participants will play motion-controlled games for 40 minutes, three times a week for eight weeks. The goal…

Researchers are studying how switching to efanesoctocog alfa (ALTUVOCT), a long-acting factor VIII therapy given once a week, affects adults and children with severe or moderate hemophilia A in routine care. The study tracks factor use, treatment satisfaction, and quality of life…

This observational study will take small liver samples from 8 adults with hemophilia A or B who had gene therapy at least 6 months ago. Researchers want to see how the gene therapy affected liver cells, including how many cells still carry the therapy and whether there is any liv…

This study looks back at medical records of people with congenital thrombotic thrombocytopenic purpura (cTTP), a rare inherited blood disorder that causes dangerous blood clots. Participants received a manufactured version of the missing ADAMTS13 enzyme through an early access pr…

This study looks at hemophilia A patients who have used Coageight, a recombinant factor VIII treatment, to see how many develop inhibitors, which are antibodies that block the treatment's effect. Researchers will test blood samples from about 262 male patients aged 2 and older wh…

This study uses ultrasound to examine the joints of adults with mild hemophilia, a group that often goes understudied. Researchers will scan six joints (ankles, knees, elbows) to look for early signs of damage that may not cause symptoms yet. The goal is to see how common joint p…

This study compares how well adults with hemophilia (ages 18–35) perform a 30-second sit-to-stand test versus healthy peers of the same age. The goal is to see if this simple test can detect differences in leg strength and endurance linked to joint damage from bleeding. Participa…

This study looks at children with immune thrombocytopenic purpura (ITP) who also have certain antibodies, as they are at higher risk of developing lupus. Researchers will analyze blood samples to track immune cell changes and markers that may signal the transition to lupus. The g…

This study tests a smart sharps disposal container that helps hemophilia patients safely throw away used needles at home. About 23 adults with moderate or severe hemophilia will use the device for several weeks. Researchers want to see if patients find it easy to use and if they …

This observational study looks at children with moderate or severe hemophilia A who are on one of two preventive treatments: a longer-acting factor VIII therapy (efanesoctocog alfa) or a non-factor therapy (emicizumab). Researchers want to see if there are differences in how well…

This study looks at how the sedative dexmedetomidine affects the smallest blood vessels in people with septic shock, a life-threatening condition caused by severe infection. Researchers will measure blood flow in the tongue's tiny vessels and other key blood pressure indicators b…

This study asks adults with haemophilia A in Germany to complete an online survey about their preferences for preventive treatments. Participants choose between hypothetical treatment options that vary in effectiveness, safety, and how they are given. The goal is to understand wh…

This pilot study will test a drug called anisodamine in 20 adults with septic shock who are on a ventilator. The goal is to see if the drug can improve blood flow in small blood vessels and help with a phenomenon called 'vascular waterfall.' This is a very early study to gather i…

This study will collect blood samples and medical information from 600 adults with rare diseases affecting blood vessels in the brain and eye, such as CADASIL and cavernous angioma. The goal is to create a long-term biobank that researchers can use to find biomarkers and better u…

This study looks at whether a new test called T-TAS can help predict bleeding after heart surgery. Researchers will take blood samples from 30 adults before, right after, and 24 hours after surgery. They will compare T-TAS results with standard tests and track how much bleeding a…

This study will follow 50 men with severe hemophilia A for five years to compare bone density between those taking emicizumab and those taking efanesoctocog alfa. Researchers will also measure bone remodeling markers and joint health. The goal is to see if one treatment is linked…

This study aims to find the best dose of a clotting drug (fibrinogen) for patients after heart surgery using a heart-lung machine. Bleeding is a common complication, and current dosing is not personalized. Researchers will take blood samples from 150 adults to understand how fibr…

This observational study will follow 500 children with hemophilia A who use non-factor therapy to prevent bleeding. Researchers want to understand why some children develop antibodies against factor VIII while others do not. By studying blood and stool samples over time, they hop…

This study will compare how well an artificial intelligence (AI) system and human experts interpret ROTEM tests, which measure blood clotting in patients undergoing surgery or in critical care. Researchers will enroll 400 adults and assess agreement on whether a clotting problem …

This study is creating an AI tool to help doctors decide the best heart treatment for people who have both immune thrombocytopenia (ITP) and coronary artery disease. Researchers will look at past patient data to build the tool, then test it on 600 new patients. The goal is to bet…

This study looks at whether the two-minute step test is a reliable way to measure aerobic endurance in people with hemophilia. Researchers will test 35 people aged 6–18 with hemophilia A or B, comparing the step test with other measures like walking tests and balance assessments.…

This study will follow about 70 people with hemophilia A who are already taking emicizumab to prevent bleeding. Researchers will use ultrasound to check for early joint damage in elbows, knees, and ankles that are currently healthy. The goal is to see how often joint damage appea…

This study follows 75 young adults with severe hemophilia who were part of an earlier study as teens. Researchers want to see if their healthcare habits change as they become adults and what factors help them stick to treatment. The goal is to understand how to support a smooth t…

This study will look at how common von Willebrand disease is among children in Upper Egypt, what symptoms they have, and how they are treated. Researchers will review medical records and lab tests from 25 children aged 0-18 with suspected or confirmed VWD. The goal is to improve …

This study looks back at the medical records of 50 adult ICU patients with COVID-19 who needed a life-support machine called ECMO. The goal is to understand how often bleeding and dangerous blood clots happen, and how blood transfusions and blood thinners affect their care. The f…

This study aims to create a simple blood test-based guide to help doctors manage bleeding during open heart surgery. Researchers will use leftover blood samples from 140 patients to see if a special test (thromboelastography) can better direct the use of blood products like plate…

This study will enroll 70 Egyptian children with hemophilia to see if an oral health education program improves their dental health and quality of life. The program teaches proper oral care based on guidelines from dental and hemophilia organizations. Researchers will measure cav…

This study looks at whether young people (ages 8–25) with chronic immune thrombocytopenic purpura (ITP) have lower aerobic fitness than healthy peers. Fatigue is a major problem for many with ITP, and the researchers want to see if it's linked to a 'vicious cycle' of being less a…

This study looks at two genes (IL-1β and IL-33) in 300 adults with low platelet counts caused by either primary immune thrombocytopenia (ITP) or lupus (SLE). Researchers will measure gene activity from a blood sample to see if these genes can help tell the two conditions apart. T…

This study aims to discover new reasons why blood clots form in people with heart disease, diabetes, and other illnesses. Researchers will analyze blood samples from 200 patients with narrowed neck arteries to look for markers of cell damage and clotting factors. The goal is to f…

This study will compare MRI scans with standard X-rays to see which method better detects knee joint damage in adults with hemophilia who have had repeated bleeding in the knee. Researchers will use special scoring systems to measure early and advanced joint changes. The goal is …

This study aims to find out if some women who had severe bleeding after a vaginal delivery have an undiagnosed bleeding disorder. Researchers will test blood samples from 150 women who lost at least 1000 mL of blood during or after birth in the past year. The goal is to better un…

This study will look at 100 adults with low platelet counts to see how many have an enlarged spleen and whether that affects their symptoms, complications, or response to treatment. The goal is to better understand the role of the spleen in these blood disorders. No new treatment…

This study will measure vitamin D levels in 84 adults newly diagnosed with immune thrombocytopenia (ITP), a bleeding disorder. Researchers want to see if vitamin D levels are linked to how well patients respond to first-line steroid therapy. The goal is to gather knowledge, not t…

This study will enroll 850 adults over 65 who have had a heart attack (acute coronary syndrome). Researchers want to see if adding frailty measurements to standard risk scores improves the prediction of serious bleeding during the hospital stay and up to 6 months later. The goal …